2024-04-27

Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting​

2023-05-05

Arbele celebrates its 7th anniversary as a clinical-stage immunotherapy biotech and the opening of TibTech, its cancer diagnostics subsidiary

2022-08-10

Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers​

2021-02-02

雙抗體免疫治療 腸胃癌治療的未來方向

2020-10-12

StartupBeat Policy: 創科界籲政策扶持勿只派錢

2020-10-12

Arbele Newsletter Oct-2020 (Issue No.2)

2020-06-11

Avalon GloboCare Announces Three-Way Material Transfer Agreement with Weill Cornell Medicine and Arbele Limited for Development of Next Generation Cellular Immunotherapy FLASH-CAR(TM) Technology

error: Content is protected !!